Q3 2017 EPS Estimates for TESARO, Inc. Cut by Analyst (NASDAQ:TSRO)

TESARO, Inc. (NASDAQ:TSRO) – Equities research analysts at SunTrust Banks dropped their Q3 2017 earnings estimates for TESARO in a research report issued on Tuesday. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will post earnings of ($2.57) per share for the quarter, down from their prior estimate of ($1.51). SunTrust Banks also issued estimates for TESARO’s Q4 2017 earnings at ($2.47) EPS, FY2017 earnings at ($10.40) EPS, FY2018 earnings at ($5.26) EPS and FY2019 earnings at ($1.50) EPS.

TSRO has been the topic of a number of other research reports. BidaskClub lowered TESARO from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Robert W. Baird restated a “neutral” rating on shares of TESARO in a research report on Tuesday, June 6th. Bank of America Corporation restated a “buy” rating and set a $154.00 price objective on shares of TESARO in a research report on Tuesday, June 20th. Wedbush upgraded TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a research report on Monday, June 5th. Finally, ValuEngine lowered TESARO from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $176.35.

WARNING: “Q3 2017 EPS Estimates for TESARO, Inc. Cut by Analyst (NASDAQ:TSRO)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2800943/q3-2017-eps-estimates-for-tesaro-inc-cut-by-analyst-nasdaqtsro.html.

TESARO (NASDAQ TSRO) opened at 110.89 on Friday. The company’s market cap is $5.99 billion. TESARO has a 12-month low of $83.26 and a 12-month high of $192.94. The company has a 50-day moving average price of $131.54 and a 200 day moving average price of $149.39.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.30. The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. TESARO’s revenue was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.28) EPS.

In other TESARO news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 40.50% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Trellus Management Company LLC acquired a new stake in shares of TESARO during the first quarter valued at approximately $1,154,000. Tocqueville Asset Management L.P. raised its stake in shares of TESARO by 11.1% in the first quarter. Tocqueville Asset Management L.P. now owns 62,055 shares of the biopharmaceutical company’s stock valued at $9,548,000 after buying an additional 6,225 shares during the last quarter. Whittier Trust Co. raised its stake in shares of TESARO by 4.8% in the first quarter. Whittier Trust Co. now owns 11,186 shares of the biopharmaceutical company’s stock valued at $1,721,000 after buying an additional 515 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of TESARO by 3.9% in the first quarter. Russell Investments Group Ltd. now owns 25,329 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 954 shares during the last quarter. Finally, Strs Ohio raised its stake in shares of TESARO by 11.6% in the first quarter. Strs Ohio now owns 4,800 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 500 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.